Since their initial explosion onto the market, there is a growing pipeline demonstrating the promise of aptamer therapeutics across…

Protein-protein interactions were once considered undruggable. Our tailored aptamer selection approach is proving this isn’t so. Targets such as transcription factors, immune checkpoints in oncology, infectious disease agents, and…

Finding the right affinity ligand pair is a bottleneck in immunoassay development where the Optimer platform can help. Whether you need an additional reagent to form an aptamer-antibody pair or…

When developing an aptamer to a protein target it’s important to keep in mind how you want to use it as much as what you want to bind. When developing…

April 25th is DNA day. This day celebrates the completion of the Human Genome Project 20 years ago and the discovery of DNA’s double helix 70 years ago,…

The passing of the FDA Modernization Act 2.0 is a commitment to reducing the use of animals in drug testing. The act allows researchers to use…

One of the key benefits of using aptamers instead of antibodies is how you store and use your reagent. Over the past 60 years the stability of oligonucleotides has…

As we come to the end of 2022 and our first year as a listed company, the year in review shows a clear theme of growth and expansion across…

Drugs of abuse tests require highly selective, robust assays. Aptamers are helping to deliver new assays for more sensitive and simpler tests. According to the UN Office on Drugs…

Constraining an Optimer to a specific structure confers various benefits to the ligand that researchers can use for increased assay performance. Constrained Optimer structures Optimer binders are single-stranded oligonucleotides that can…